FIELD: gene engineering.
SUBSTANCE: invention relates to a group of compounds represented by structural formulas in claim 1 with agonistic biological activity of the stimulator of interferon genes (STING) that can find their use in medicine in the treatment of tumors in patients suffering from them.
EFFECT: obtaining agonists of sting interferon gene stimulator.
3 cl, 3 dwg, 3 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
BICYCLIC AGONISTS OF STING INTERFERON GENE STIMULATOR | 2020 |
|
RU2813691C2 |
BICYCLIC AGONISTS OF THE INTERFERON GENE STIMULATOR STING | 2020 |
|
RU2800072C1 |
ENPP1 INHIBITORS AND METHODS OF MODULATING THE IMMUNE RESPONSE | 2018 |
|
RU2800798C2 |
BENZOTHIOPHENES AND RELATED COMPOUNDS AS STING AGONISTS | 2019 |
|
RU2806274C2 |
SELECTIVE ESTROGEN RECEPTOR INHIBITORS AND USE THEREOF | 2017 |
|
RU2734501C2 |
INHIBITORS, A METHOD OF THEIR PREPARATION AND USE | 2019 |
|
RU2806033C2 |
NEW QUINOLINE COMPOUNDS | 2018 |
|
RU2810113C2 |
SUBSTITUTED AROMATIC DERIVATIVE WITH CONDENSED RINGS AND COMPOSITION INCLUDING IT AND THEIR USE | 2020 |
|
RU2811484C1 |
MACROCYCLIC TYROSINE KINASE INHIBITOR AND ITS USE | 2019 |
|
RU2798231C2 |
THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | 2005 |
|
RU2374242C2 |
Authors
Dates
2023-12-06—Published
2019-02-21—Filed